Snapshot A 27-year-old female presents to the emergency department at 11 weeks of gestation with 2 days of uterine bleeding and pelvic pressure, as well as multiple daily episodes of nonbloody, nonbilious emesis over the past week. The patient states that the bleeding is like heavy spotting with dark, purplish-colored blood. On exam, the uterus is larger than expected for gestational age. An ultrasound is performed and shows multiple anechoic spaces in the uterus with no fetus visualized. Introduction Overview a type of gestational trophoblastic disease (GTD) molar pregnancies are considered premalignant when malignant, are termed gestational trophoblastic neoplasia (GTN) e.g., choriocarcinoma originates in the placenta has the potential to invade the uterus and metastasize Classification Complete mole 46,XX or 46,XY an empty ovum fertilized by a single sperm results in duplication of paternal genetic material (all DNA is from sperm) higher risk of transformation into choriocarcinoma 15-20% transform Partial mole 69,XXX, 69,XXY, or 69,XYY a normal ovum is fertilized by 2 sperm less likely to transform into choriocarcinoma 1-5% transform Epidemiology Incidence 66-121 per 100,000 pregnancies Demographics higher rates in Latin American, Asian, and Middle Eastern countries Risk factors extremes of maternal age history of previous mole Presentation Symptoms exaggeration of normal pregnancy symptoms due to extremely high β-hCG hyperemesis gravidarum extreme nausea and vomiting vaginal bleeding "prune juice" discharge due to accumulated blood in uterine cavity that has oxidized and liquified pelvic discomfort pain or pressure Physical Exam pelvic exam uterus larger than expected for gestational age more common in complete mole possible adnexal mass possible grape-like mass in vagina Imaging Transvaginal ultrasound (TVUS) indications β-hCG > 100,000 mIU/mL findings central heterogeneous mass with numerous discrete anechoic spaces “snowstorm,” “cluster of grapes,” or “honeycomb” appearance on older ultrasounds if partial mole fetal parts and amniotic fluid abnormally wide gestational sac abnormal-looking placenta ovarian theca-lutein cysts more likely in complete mole Studies ↑ β-hCG (> 100,000 mIU/mL) complete mole > partial mole Differential Normal pregnancy key distinguishing factors uterus sized appropriately for gestation β-hCG will be within normal pregnancy range uterine pregnancy visualized on ultrasound Spontaneous abortion key distinguishing factors β-hCG will be normal or decreased uterine pregnancy visualized on ultrasound +/- open cervical os on exam +/- vaginal passage of fetal parts Treatment Medical RhoGAM indications all Rh(D)-negative mothers with vaginal bleeding if father is Rh(D)-positive or unknown modalities single intramuscular or intravenous dose Surgical suction and curettage indications both diagnostic and therapeutic first line treatment for mole pathology confirms diagnosis Follow-Up trend weekly β-hCG levels indications all patients with confirmed mole and/or elevated β-hCG if continues to uptrend workup for choriocarcinoma Complications Choriocarcinoma malignant product of gestational contents very high β-hCG that does not downtrend after surgical treatment for mole can metastasize to lungs and brain requires surgery and chemotherapy Ovarian theca-lutein cysts bilateral, multicystic ovaries, often septated secondary to β-hCG stimulation can cause hyperandrogenism also associated with multigestational pregnancy, polycystic ovarian syndrome (PCOS), and ovulation induction due to stimulation by elevated levels of β-hCG Hyperthyroidism Preeclampsia Respiratory distress usually secondary to trophoblastic embolization